Select Language
Free Registration
My Cart

Latent TGF-beta 2

Latent TGF-beta 2 Overview

English NameTransforming growth factor beta 2Approved Drugs0
Drugs in Clinical Trials6Target SynonymTGF-beta-2，BSC-1 Cell Growth Inhibitor，Polyergin，Glioblastoma-Derived T-Cell Suppressor Factor，Cetermin，LDS4，TGFB2，Transforming Growth Factor， Beta 2，Transforming Growth Factor Beta-2 Proprotein，TGF-Beta2，Transforming Growth Factor Beta 2，G-TSF，Transforming Growth Factor beta2，LAP，Prepro-Transforming Growth Factor Beta-2
Highest Development StagePhase 3 Clinical
English NameTransforming growth factor beta 2
Target SynonymTGF-beta-2，BSC-1 Cell Growth Inhibitor，Polyergin，Glioblastoma-Derived T-Cell Suppressor Factor，Cetermin，LDS4，TGFB2，Transforming Growth Factor， Beta 2，Transforming Growth Factor Beta-2 Proprotein，TGF-Beta2，Transforming Growth Factor Beta 2，G-TSF，Transforming Growth Factor beta2，LAP，Prepro-Transforming Growth Factor Beta-2
Approved Drugs0
Drugs in Clinical Trials6
Highest Development StagePhase 3 Clinical

Latent TGF-beta 2 Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeatureOrder Now
TG2-H5243
Human
HEK293
Human Latent TGF-beta 2 / TGFB2 Protein, His Tag
 Add to Cart
Total: 1
  • 1

Latent TGF-beta 2 Background

Transforming growth factor beta 2 ( TGFB2) is also known as TGF-β2, G-TSF, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The TGFB2 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB2 protein can inhibit the T cell growth by IL-2-dependent. and can inhibit immune surveillance during tumor development, the protein promoting tumor growth with an autocrine manner. TGF-β2 can affect the viability of killer cells and reduce the expression of IL-2, IL-6, IL-10, IFN-γ and other cytokines.TGFB2 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages.

Latent TGF-beta 2 Synonyms

Latent TGFB2,MGC116892,TGFβ2,TGF-beta2

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
TrabedersenAP 2/09-DS; AP-12009; OT-201; AP-2/09; AP-2/09-DS; OT-101Phase 3 ClinicalIsarna Therapeutics GmbhAstrocytoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Diffuse Intrinsic Pontine Glioma; Glioblastoma; Lung Neoplasms; Melanoma; Mesothelioma; Pancreatic Neoplasms; Solid tumours
Details
Bintrafusp alfaM-7824; GSK-4045154; MSB-0011359CPhase 3 ClinicalMerck SeronoAnus Neoplasms; Biliary Tract Neoplasms; Brain metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Esthesioneuroblastoma, Olfactory; Gallbladder Neoplasms; Ganglioglioma; Head and Neck Neoplasms; Hematologic Neoplasms; Intestinal Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Microsatellite Instability; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Nose Neoplasms; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Penile Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Respiratory papillomatosis; Sarcoma; Sarcoma, Kaposi; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymic epithelial tumor; Thymoma; Thymus Neoplasms; Triple Negative Breast Neop
Details
NisevokitugNIS-793Phase 3 ClinicalXoma CorpAdenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential
Details
ISTH-0036ISTH-0036Phase 2 ClinicalIsarna Therapeutics GmbhDiabetic macular oedema; Glaucoma, Open-Angle; Wet Macular Degeneration
Details
Tosposertib phosphateTU-2218; NCE401; NCE-401Phase 2 ClinicalTiumBio Co LtdIdiopathic Pulmonary Fibrosis; Solid tumours
Details
LP-008LP-008Phase 1 ClinicalLepu Biopharma Co LtdSolid tumours
Details
  • Overview
  • Product List
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland